Equities research analysts expect Medidata Solutions Inc (NASDAQ:MDSO) to post $167.88 million in sales for the current quarter, Zacks reports. Six analysts have provided estimates for Medidata Solutions’ earnings. The highest sales estimate is $168.72 million and the lowest is $166.60 million. Medidata Solutions posted sales of $141.22 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 18.9%. The company is expected to report its next quarterly earnings results on Thursday, February 14th.
According to Zacks, analysts expect that Medidata Solutions will report full-year sales of $636.62 million for the current financial year, with estimates ranging from $635.10 million to $638.00 million. For the next financial year, analysts anticipate that the company will post sales of $755.59 million, with estimates ranging from $746.30 million to $760.20 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Medidata Solutions.
Medidata Solutions (NASDAQ:MDSO) last released its earnings results on Thursday, October 18th. The company reported $0.42 earnings per share for the quarter, topping the consensus estimate of $0.36 by $0.06. The business had revenue of $163.41 million for the quarter, compared to the consensus estimate of $162.09 million. Medidata Solutions had a net margin of 8.43% and a return on equity of 10.70%. The firm’s quarterly revenue was up 17.6% compared to the same quarter last year. During the same period last year, the firm posted $0.33 earnings per share.
In related news, EVP Michael I. Otner sold 7,030 shares of the business’s stock in a transaction that occurred on Tuesday, October 23rd. The shares were sold at an average price of $69.40, for a total transaction of $487,882.00. Following the transaction, the executive vice president now directly owns 62,548 shares of the company’s stock, valued at $4,340,831.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 4.70% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in MDSO. Dimensional Fund Advisors LP grew its position in Medidata Solutions by 0.5% during the first quarter. Dimensional Fund Advisors LP now owns 130,588 shares of the company’s stock valued at $8,202,000 after purchasing an additional 663 shares in the last quarter. Principal Financial Group Inc. grew its position in Medidata Solutions by 3.5% during the first quarter. Principal Financial Group Inc. now owns 259,770 shares of the company’s stock valued at $16,316,000 after purchasing an additional 8,753 shares in the last quarter. World Asset Management Inc purchased a new position in Medidata Solutions during the second quarter valued at approximately $235,000. Amalgamated Bank grew its position in Medidata Solutions by 15.7% during the second quarter. Amalgamated Bank now owns 9,423 shares of the company’s stock valued at $759,000 after purchasing an additional 1,282 shares in the last quarter. Finally, Cornerstone Wealth Management LLC purchased a new position in Medidata Solutions during the second quarter valued at approximately $285,000.
Medidata Solutions stock opened at $72.45 on Friday. The company has a market capitalization of $4.43 billion, a PE ratio of 75.47, a PEG ratio of 4.28 and a beta of 1.30. The company has a current ratio of 2.52, a quick ratio of 2.52 and a debt-to-equity ratio of 0.15. Medidata Solutions has a fifty-two week low of $59.60 and a fifty-two week high of $88.87.
About Medidata Solutions
Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development of new therapies. The company's platform solutions include data capture and management and trial planning and management.
See Also: What Does Beta Mean In Stock Selection
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.